COMMUNIQUÉS West-GlobeNewswire

PL BioScience Announces new Board Member Ole Henrik Bang-Andreasen
28/10/2025
AACHEN, Germany, Oct. 28, 2025 (GLOBE NEWSWIRE) -- PL BioScience GmbH, a German life science company specializing in the production and development of Human Platelet Lysate (HPL) for cell expansion and manufacturing, [...]
Upgrade of guidance
28/10/2025
ANNOUNCEMENT NO. 295 28 October 2025 Upgrade of guidance ChemoMetec experiences an increased interest in its technology, not the least the XcytoMatic platform, and consequently expects a positive trend in revenue and [...]
Orion Group Interim Report January–September 2025
28/10/2025
ORION CORPORATION INTERIM REPORT 1–9/2025 28 OCTOBER 2025 at 12:00 EET Orion Group Interim Report January–September 2025 July–September 2025 Highlights Net sales totalled EUR 423.2 (July–September 2024: 471.3) million [...]
Zymeworks Announces Participation in Upcoming Investor Conferences
28/10/2025
VANCOUVER, British Columbia, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the [...]
Bavarian Nordic Provides Further Support to Mpox Outbreak in Africa through Additional Donation of Vaccines
28/10/2025
COPENHAGEN, Denmark, October 28, 2025 – Bavarian Nordic announced today a donation of mpox vaccines to Africa CDC to support the response to the ongoing mpox outbreak in Africa. The donation of 110,000 doses of the [...]
Swarm Oncology announces research collaboration with a leading hospital to advance T cell therapies for advanced solid cancers
28/10/2025
London, United Kingdom October 28, 2025, Swarm Oncology Ltd. (“Swarm Oncology” or “Swarm”), a biotechnology company pioneering novel T cell therapies to achieve long-term remission in patients with advanced solid [...]
Novartis announces expiration of Tourmaline Bio tender offer
28/10/2025
Basel, October 28 2025 - Novartis today announced that its previously announced tender offer (the “offer”) by Torino Merger Sub Inc., a Delaware corporation and an indirect wholly owned subsidiary of Novartis (“ [...]
Kyowa Kirin and Orchard Therapeutics Announce OTL-200 Granted Orphan Regenerative Medicine Product Designation for Early-onset MLD in Japan
28/10/2025
– First and only disease-modifying therapy for the treatment of eligible children with MLD also receives Orphan Drug Designation and Priority Review in the Kingdom of Saudi Arabia – TOKYO, LONDON and BOSTON, Oct. 28, [...]
Novartis delivers solid sales and core operating income growth with strong pipeline progress in Q3; reaffirms FY 2025 guidance
28/10/2025
Ad hoc announcement pursuant to Art. 53 LR Q3 net sales grew +7% (cc 1 , +8% USD) and core operating income 1 grew +7% (cc, +6% USD) Sales growth was driven by continued strong execution on priority brands including [...]
Press release: Sanofi successfully prices USD 3 billion of bond issue
28/10/2025
Sanofi successfully prices USD 3 billion of bond issue Paris, France – October 28, 2025 - Sanofi announces that it has successfully priced its offering of $3 billion of notes across 5 tranches: $400 million fixed rate [...]
Communiqué de presse : Sanofi place 3 milliards de dollars d’emprunts obligataires
28/10/2025
Sanofi place 3 milliards de dollars d’emprunts obligataires Paris, 28 Octobre 2025 - Sanofi annonce avoir placé avec succès une émission obligataire en 5 tranches (les « obligations ») pour un montant de 3 milliards de [...]
Positive phase III results for Roche’s Gazyva/Gazyvaro in children and young adults with idiopathic nephrotic syndrome
28/10/2025
Gazyva/Gazyvaro versus mycophenolate mofetil shows significantly more children and young adults achieved sustained complete remission at week 52 If approved, Gazyva/Gazyvaro could help children and young adults sustain [...]
Qualigen Therapeutics to Rebrand as AIxCrypto After Stockholder Meeting on November 12, with Three Core Goals for 2025
28/10/2025
Dubai, UAE / Beijing, China, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics Inc. (NASDAQ: QLGN) (“Qualigen”, “QLGN” or the “Company”), a publicly-traded technology company majority owned by Faraday Future [...]
Présentation du tout premier grand modèle de langage multiomique au monde au salon Global Health Exhibition de Riyad, ou la promesse d’un décodage du langage de la biologie humaine
28/10/2025
Entraîné à partir de données multiomiques, le modèle fondamental de PanOmiQ représente une percée grâce à son déploiement alimenté par des composants logiques programmables (ou FPGA, de l’anglais Field-Programmable Gate [...]
Anteris Technologies Announces First Patients Treated in DurAVR® THV Global Pivotal Trial (the “PARADIGM Trial”)
27/10/2025
MINNEAPOLIS, United States and BRISBANE, Australia, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. ( Anteris or the Company ) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to [...]
Aurora Spine Launches New Biologics Portfolio
27/10/2025
New Aurora Biologics Division Establishes Aurora Spine as a Vertically Integrated Source for Spinal Implants and Biologics CARLSBAD, CA, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Aurora Spine Corporation (“Aurora Spine”) (TSXV [...]
Elixir Medical Announces Significant Late Breaking Clinical Results for DynamX® Bioadaptor Demonstrating Nearly 50% Reduction in Coronary Event Rates vs. Current PCI Standard of Care
27/10/2025
Results were presented at the Transcatheter Cardiovascular Therapeutics (TCT) Conference 2025 in San Francisco on October 27, 2025 DynamX® bioadaptor is the first interventional technology to demonstrate significant [...]
Elixir Medical annonce de nouveaux résultats cliniques significatifs pour le DynamX® Bioadaptor, démontrant une réduction de près de 50 % des taux d’événements coronariens par rapport à la norme actuelle de soins ICP
27/10/2025
Les résultats ont été présentés lors de la Transcatheter Cardiovascular Therapeutics (TCT) Conference 2025 à San Francisco, le 27 octobre 2025 Le DynamX® Bioadaptor est la première technologie interventionnelle à [...]
Amwell® to report third quarter 2025 operating results; company leaders to attend upcoming investor conferences
27/10/2025
BOSTON, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Amwell ® (NYSE: AMWL), a leading provider of a comprehensive SaaS-based software platform for technology-enabled healthcare, will report third quarter 2025 operating results [...]

Pages